Skip to main content

Advertisement

SpringerLink
Log in

Alternative dosing regimens for atezolizumab: right dose, wrong frequency

  • Editorial
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

The population pharmacokinetics of atezolizumab demonstrate that the trough concentrations are well above the putative target of 6 µg/ml. Thus, alternative dosing schedules are indeed of interest, focusing on reducing the frequency to allow greater patient convenience and reduced costs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Morrissey KM, Marchand M, Patel H, Zhang R, Wu B, Chan HP, Mecke A, Girish S, Jin JY, Winter HR, Bruno R (2019) Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. Cancer Chemother Pharmacol. https://doi.org/10.1007/s00280-019-03954-8

    Article  PubMed  Google Scholar 

  2. Ratain MJ, Goldstein DA, Lichter AS (2019) Interventional pharmacoeconomics: a new discipline for a cost-constrained environment. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2019.1341

    Article  PubMed  Google Scholar 

  3. Ratain MJ, Goldstein DA (2018) Time is money: optimizing the scheduling of nivolumab. J Clin Oncol. https://doi.org/10.1200/JCO.18.00045:JCO1800045

    Article  PubMed  PubMed Central  Google Scholar 

  4. Deng R, Bumbaca D, Pastuskovas CV, Boswell CA, West D, Cowan KJ, Chiu H, McBride J, Johnson C, Xin Y, Koeppen H, Leabman M, Iyer S (2016) Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. MAbs 8(3):593–603. https://doi.org/10.1080/19420862.2015.1136043

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515(7528):558–562. https://doi.org/10.1038/nature13904

    Article  CAS  PubMed  Google Scholar 

  6. Spigel DR, Gettinger SN, Horn L, Herbst RS, Gandhi L, Gordon MS, Cruz C, Conkling P, Cassier PA, Antonia SJ, Burris HA, Fine GD, Mokatrin A, Kowanetz M, Shen X, Chen DS, Soria J-C (2013) Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 31(15):8008. https://doi.org/10.1200/jco.2013.31.15_suppl.8008

    Article  Google Scholar 

  7. Li H, Yu J, Liu C, Liu J, Subramaniam S, Zhao H, Blumenthal GM, Turner DC, Li C, Ahamadi M, de Greef R, Chatterjee M, Kondic AG, Stone JA, Booth BP, Keegan P, Rahman A, Wang Y (2017) Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response. J Pharmacokinet Pharmacodyn 44(5):403–414. https://doi.org/10.1007/s10928-017-9528-y

    Article  CAS  PubMed  Google Scholar 

  8. Liu C, Yu J, Li H, Liu J, Xu Y, Song P, Liu Q, Zhao H, Xu J, Maher VE, Booth BP, Kim G, Rahman A, Wang Y (2017) Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis. Clin Pharmacol Ther 101(5):657–666. https://doi.org/10.1002/cpt.656

    Article  CAS  PubMed  Google Scholar 

  9. Ogasawara K, Newhall K, Maxwell SE, Dell’Aringa J, Komashko V, Kilavuz N, Delarue R, Czuczman M, Sternas L, Rose S, Beach CL, Novick S, Zhou S, Palmisano M, Li Y (2019) Population pharmacokinetics of an anti-PD-L1 antibody, durvalumab in patients with hematologic malignancies. Clin Pharmacokinet 1:5–9. https://doi.org/10.1007/s40262-019-00804-x

    Article  CAS  Google Scholar 

  10. Baverel PG, Dubois VFS, Jin CY, Zheng Y, Song X, Jin X, Mukhopadhyay P, Gupta A, Dennis PA, Ben Y, Vicini P, Roskos L, Narwal R (2018) Population pharmacokinetics of durvalumab in cancer patients and association with longitudinal biomarkers of disease status. Clin Pharmacol Ther 103(4):631–642. https://doi.org/10.1002/cpt.982

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Tel Aviv University, Tel Aviv, Israel

    Daniel A. Goldstein

  2. Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel

    Daniel A. Goldstein

  3. Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, USA

    Daniel A. Goldstein

  4. The University of Chicago, 5841 S Maryland Ave, MC 2115, Chicago, IL, 60637, USA

    Mark J. Ratain

Authors
  1. Daniel A. Goldstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark J. Ratain
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark J. Ratain.

Ethics declarations

Conflict of interest

M.J.R. reports grants from AbbVie, personal fees from Aptevo, personal fees from Cyclacel, other from BeiGene, grants from Dicerna, personal fees from multiple generic pharmaceutical companies, grants from Genentech, personal fees from Pneuma Respiratory, outside the submitted work; and Co-founder and Director, Value in Cancer Care Consortium (Vi3C, www.vi3c.org). D.A.G. declares that he has no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article refers to online published article available at https://doi.org/10.1007/s00280-019-03954-8.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Goldstein, D.A., Ratain, M.J. Alternative dosing regimens for atezolizumab: right dose, wrong frequency. Cancer Chemother Pharmacol 84, 1153–1155 (2019). https://doi.org/10.1007/s00280-019-03971-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-019-03971-7

Keywords

Search

Navigation